BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 36913260)

  • 21. Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations.
    Shi C; Zhang C; Fu Z; Liu J; Zhou Y; Cheng B; Wang C; Li S; Zhang Y
    Acta Pharm Sin B; 2023 Jun; 13(6):2613-2627. PubMed ID: 37425047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracranial complete remissions in an aumolertinib-treated
    Shan X; Wu Y; Liu J
    Transl Cancer Res; 2023 Feb; 12(2):434-438. PubMed ID: 36915577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
    Eskilsson E; Røsland GV; Solecki G; Wang Q; Harter PN; Graziani G; Verhaak RGW; Winkler F; Bjerkvig R; Miletic H
    Neuro Oncol; 2018 May; 20(6):743-752. PubMed ID: 29040782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.
    Lv Y; Zhang J; Liu F; Song M; Hou Y; Liang N
    Medicine (Baltimore); 2019 May; 98(22):e15749. PubMed ID: 31145289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
    Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
    Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
    She L; Gong X; Su L; Liu C
    Oncologist; 2023 Jan; 28(1):e45-e53. PubMed ID: 36181764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
    Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glioma targeted therapy: insight into future of molecular approaches.
    Yang K; Wu Z; Zhang H; Zhang N; Wu W; Wang Z; Dai Z; Zhang X; Zhang L; Peng Y; Ye W; Zeng W; Liu Z; Cheng Q
    Mol Cancer; 2022 Feb; 21(1):39. PubMed ID: 35135556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updated Insights on EGFR Signaling Pathways in Glioma.
    Oprita A; Baloi SC; Staicu GA; Alexandru O; Tache DE; Danoiu S; Micu ES; Sevastre AS
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
    Nagasaka M; Zhu VW; Lim SM; Greco M; Wu F; Ou SI
    J Thorac Oncol; 2021 May; 16(5):740-763. PubMed ID: 33338652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.
    Wang Y; Liang D; Chen J; Chen H; Fan R; Gao Y; Gao Y; Tao R; Zhang H
    Oncologist; 2021 Mar; 26(3):173-177. PubMed ID: 32949176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
    Yang JC; Camidge DR; Yang CT; Zhou J; Guo R; Chiu CH; Chang GC; Shiah HS; Chen Y; Wang CC; Berz D; Su WC; Yang N; Wang Z; Fang J; Chen J; Nikolinakos P; Lu Y; Pan H; Maniam A; Bazhenova L; Shirai K; Jahanzeb M; Willis M; Masood N; Chowhan N; Hsia TC; Jian H; Lu S
    J Thorac Oncol; 2020 Dec; 15(12):1907-1918. PubMed ID: 32916310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular targeted therapy of glioblastoma.
    Le Rhun E; Preusser M; Roth P; Reardon DA; van den Bent M; Wen P; Reifenberger G; Weller M
    Cancer Treat Rev; 2019 Nov; 80():101896. PubMed ID: 31541850
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.